FLT3 Gene Mutation Analysis at Chughtai Lab

FLT3 Gene Mutation Analysis at Chughtai Lab

The FLT3 Gene Mutation Analysis at Chughtai Lab is a highly specialized molecular diagnostic test designed to detect critical genetic alterations in the Fms-like tyrosine kinase 3 (FLT3) gene. This gene encodes a class III receptor tyrosine kinase that plays a pivotal role in the proliferation, survival, and differentiation of hematopoietic progenitor cells. Under normal physiological conditions, the binding of the FLT3 ligand to its receptor triggers a highly regulated signaling cascade, including the activation of downstream pathways such as PI3K/Akt, MAPK/ERK, and STAT5. However, somatic mutations in the FLT3 gene lead to constitutive, ligand-independent activation of the receptor, driving the uncontrolled clonal expansion of immature myeloid cells, known as myeloblasts.

FLT3 mutations are among the most frequent genetic abnormalities identified in Acute Myeloid Leukemia (AML), occurring in approximately 30% of newly diagnosed adult patients. The two primary types of mutations evaluated by this analysis are Internal Tandem Duplications (FLT3-ITD) and Tyrosine Kinase Domain (FLT3-TKD) point mutations. FLT3-ITD mutations occur in the juxtamembrane domain (encoded by exons 14 and 15) and are characterized by the duplication of nucleotide sequences of varying lengths. FLT3-TKD mutations typically involve point mutations in the activation loop of the second kinase domain (encoded by exon 20), most commonly at codon D835 or I836. Identifying these specific mutational profiles is of paramount clinical importance, as they serve as vital biomarkers for diagnostic classification, prognostic risk stratification, and the selection of targeted therapeutic regimens.

At Chughtai Lab, this molecular analysis is performed using state-of-the-art diagnostic technologies, including Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS). These advanced methodologies provide the high sensitivity and specificity required to detect low-frequency mutant clones, calculate the FLT3-ITD allelic ratio, and identify rare sequence variants. By integrating these precise molecular findings into the clinical workflow, hematologists and oncologists across Pakistan can deliver personalized, evidence-based care tailored to the unique genetic profile of each patient’s leukemia.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure sample integrity and the accuracy of molecular diagnostic testing. Patients undergoing FLT3 Gene Mutation Analysis should observe the following guidelines:

• No Fasting Required: There is no requirement to fast before this test. You may eat, drink, and take your routine medications as prescribed by your physician.
• Clinical History Documentation: Provide the laboratory with a comprehensive clinical history, including your current diagnosis, previous cytogenetic or molecular test results, and details of any ongoing leukemia treatments.
• Transfusion and Treatment History: Inform the Chughtai Lab staff if you have recently received a blood transfusion, undergone chemotherapy, or received a hematopoietic stem cell transplant, as these interventions can influence the cellular composition of the sample.
• Medication Disclosure: Disclose all prescription medications, over-the-counter drugs, and herbal supplements you are taking, particularly any investigational drugs or targeted leukemia therapies.

During the Procedure

The FLT3 Gene Mutation Analysis can be performed on either a peripheral blood sample or a bone marrow aspirate, depending on the clinical scenario and your physician’s recommendation. The collection process is conducted under strict aseptic conditions to prevent contamination and maintain sample viability:

• Peripheral Blood Collection: If peripheral blood is used, a certified phlebotomist at Chughtai Lab will perform a standard venipuncture. A sterile needle is inserted into a vein in your arm, and approximately 3 to 5 mL of blood is collected into a tube containing ethylenediaminetetraacetic acid (EDTA) as an anticoagulant. The procedure takes only a few minutes and causes minimal discomfort, typically described as a mild pinch.
• Bone Marrow Aspiration: If a bone marrow aspirate is required, the procedure is performed by a qualified hematologist. The patient is positioned comfortably, usually lying on their side or stomach. The skin over the posterior superior iliac spine (hip bone) is thoroughly cleansed with an antiseptic solution, and a local anesthetic is injected to numb the area. A specialized bone marrow needle is then inserted to aspirate a small volume of liquid bone marrow. Patients may experience a brief, deep pressure or pulling sensation during the aspiration.
• Sample Transport and Processing: Once collected, the specimen is immediately labeled with unique patient identifiers and transported to the molecular diagnostics division of Chughtai Lab under temperature-controlled conditions. This ensures the preservation of high-quality genomic DNA for subsequent extraction and analysis.

When is a FLT3 Gene Mutation Analysis Performed?

Diagnosis of Acute Myeloid Leukemia (AML)

Physicians request a FLT3 Gene Mutation Analysis immediately upon the initial diagnosis of Acute Myeloid Leukemia (AML). Because AML is a rapidly progressive malignancy of the blood and bone marrow, establishing the molecular profile of the leukemia at the time of presentation is critical. The presence or absence of FLT3 mutations, particularly when combined with other genetic markers like NPM1 and CEBPA, helps pathologists and hematologists classify the leukemia subtype accurately, establishing a baseline for all subsequent clinical decisions.

Prognostic Stratification

The clinical course of AML is highly variable, and determining a patient’s prognosis is essential for planning the intensity of therapy. FLT3-ITD mutations are strongly associated with an adverse prognosis, characterized by a high rate of disease relapse and shorter overall survival, especially when the mutation is present in a high allelic ratio (mutant to wild-type allele ratio of 0.5 or greater) or in the absence of a co-existing NPM1 mutation. Conversely, FLT3-TKD mutations have a more variable prognostic impact. Performing this analysis allows clinicians to stratify patients into favorable, intermediate, or adverse risk categories according to international guidelines, such as the European LeukemiaNet (ELN) recommendations.

Selection of Targeted Therapy

The identification of FLT3 mutations is a critical prerequisite for the administration of targeted tyrosine kinase inhibitors (TKIs). Patients with newly diagnosed FLT3-mutated AML may benefit from the addition of first-generation TKIs, such as midostaurin, to standard induction and consolidation chemotherapy. For patients with relapsed or refractory FLT3-mutated AML, highly selective second-generation TKIs, such as gilteritinib, have demonstrated significant clinical efficacy as monotherapy. This test is therefore indispensable for identifying patients who are eligible for these life-prolonging, targeted therapeutic options.

Monitoring Minimal Residual Disease (MRD)

Following chemotherapy or a hematopoietic stem cell transplant, patients may achieve a state of complete morphological remission, where leukemia cells are no longer visible under a standard microscope. However, subclinical levels of leukemia cells, known as minimal residual disease (MRD), may persist and eventually lead to relapse. Clinicians utilize highly sensitive molecular assays to monitor FLT3 mutation levels over time. A rising level of FLT3 mutant clones during or after treatment serves as an early warning sign of impending clinical relapse, allowing for preemptive therapeutic interventions.

Evaluation of Relapsed or Refractory Leukemia

Leukemia cells are characterized by genomic instability, which can lead to clonal evolution over the course of the disease. A patient who was negative for FLT3 mutations at the time of initial diagnosis may acquire a FLT3 mutation at the time of relapse. Conversely, a patient with an initial FLT3 mutation may lose the clone or acquire secondary resistance mutations in the FLT3 kinase domain during targeted therapy. Testing at the time of relapse or when the disease becomes refractory to standard treatments is essential to reassess the molecular landscape and adjust the therapeutic strategy accordingly.

What Does a FLT3 Gene Mutation Analysis Detect?

The FLT3 Gene Mutation Analysis evaluates a comprehensive range of molecular parameters and genetic findings to provide a detailed profile of the patient’s leukemia. The analysis detects and characterizes the following clinical indicators:

• Presence or absence of the FLT3 Internal Tandem Duplication (FLT3-ITD) mutation.
• The specific size of the duplicated nucleotide sequence within the juxtamembrane domain.
• The FLT3-ITD allelic ratio, which compares the quantity of mutated DNA to wild-type DNA.
• Presence or absence of FLT3 Tyrosine Kinase Domain (FLT3-TKD) point mutations.
• Specific point mutations at codon D835 of the FLT3 gene (e.g., D835Y, D835H, D835V, D835F, D835E).
• Point mutations at codon I836 or other adjacent codons in exon 20.
• The presence of wild-type (unmutated) FLT3 alleles.
• The quality and concentration of genomic DNA extracted from the patient’s specimen.
• The efficiency of PCR amplification, verified through internal and external controls.
• Clonal heterogeneity, indicating the presence of multiple distinct FLT3-mutated subclones.
• The presence of secondary resistance mutations that may emerge during treatment with tyrosine kinase inhibitors.
• The persistence of low-level FLT3 mutations, indicating minimal residual disease (MRD) post-therapy.
• The clinical correlation with other molecular markers, such as NPM1 mutation status.
• The clinical correlation with DNMT3A mutation status, which often co-occurs with FLT3 mutations.
• The molecular response to induction and consolidation chemotherapy.
• The suitability of the patient for targeted therapies like midostaurin or gilteritinib.
• The necessity of an allogeneic hematopoietic stem cell transplant (HSCT) in first complete remission.
• The baseline molecular profile required for post-transplant chimerism and relapse monitoring.

Turnaround Time and Report Access at Chughtai Lab

At Chughtai Lab, we understand that timely results are critical when dealing with aggressive hematological malignancies like Acute Myeloid Leukemia. The FLT3 Gene Mutation Analysis is a highly complex molecular test that requires meticulous DNA extraction, PCR amplification, and fragment analysis or sequencing. The standard turnaround time for this analysis is typically 7 to 10 working days from the time of sample receipt at our central molecular diagnostics laboratory in Lahore.

Chughtai Lab offers multiple convenient methods for patients and healthcare providers to access diagnostic reports. As soon as the analysis is completed and verified by our consultant molecular pathologists, an automated SMS notification is sent to the patient’s registered mobile number. Reports can be viewed, downloaded, and printed directly from the official Chughtai Lab website (chughtailab.com) or via the user-friendly Chughtai Lab Mobile App, available on both iOS and Android platforms. Additionally, physical copies of the reports can be collected from any of our conveniently located collection centers across Pakistan, or delivered directly to your home through our dedicated report delivery service.

FLT3 Gene Mutation Analysis Findings Overview

The following table provides an overview of the parameters evaluated during the FLT3 Gene Mutation Analysis, along with their corresponding normal and abnormal clinical findings:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
FLT3-ITD Mutation Status	Not Detected (Negative for Internal Tandem Duplication)	Detected (Positive for FLT3-ITD mutation in exons 14/15)
FLT3-ITD Allelic Ratio	0.00 (No mutant alleles present)	Low Allelic Ratio (< 0.5) or High Allelic Ratio (≥ 0.5)
FLT3-TKD Mutation Status	Not Detected (Negative for Tyrosine Kinase Domain mutations)	Detected (Positive for point mutations in exon 20)
Codon D835 Mutation	Wild-type sequence (No amino acid substitution)	Point mutations resulting in D835Y, D835H, D835V, or other variants
DNA Quality and Quantity	Adequate genomic DNA concentration and high purity	Inadequate DNA yield, degradation, or presence of PCR inhibitors
PCR Amplification Control	Successful amplification of internal reference genes	Failed amplification, requiring sample re-extraction or recollection
Clonal Heterogeneity	Single wild-type population	Multiple distinct FLT3-mutated subclones detected
Minimal Residual Disease (MRD)	No detectable mutant FLT3 alleles post-treatment	Persistent or rising levels of mutant FLT3 alleles

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for FLT3 Gene Mutation Analysis?

• Advanced Molecular Pathology: Chughtai Lab utilizes state-of-the-art PCR and Next-Generation Sequencing platforms to ensure the highest diagnostic sensitivity and specificity for genetic testing.
• Expert Pathologists: Our molecular diagnostics division is led by highly qualified, board-certified consultant pathologists and molecular biologists with extensive experience in hematological genetics.
• Rigorous Quality Control: We adhere to strict international quality standards and participate in regular external quality assurance programs to guarantee the accuracy of every result.
• Comprehensive Testing Panel: Chughtai Lab offers a complete suite of leukemia diagnostics, allowing for the concurrent analysis of FLT3, NPM1, CEBPA, and other critical molecular markers.
• Nationwide Network: With a vast network of collection centers across Pakistan, patients can easily access specialized molecular testing services in Lahore, Karachi, Islamabad, and beyond.
• Convenient Report Access: Patients and clinicians can access reports securely online through our website or the Chughtai Lab Mobile App, reducing the time to initiate critical therapies.
• Home Sample Collection: We offer professional home sample collection services, allowing patients to have their blood drawn in the comfort and safety of their homes.
• Patient-Centered Care: At Chughtai Lab, we prioritize patient comfort, confidentiality, and compassionate care throughout the entire diagnostic journey.